Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Semin Arthritis Rheum.

Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Segura JL, Julià A, Marsal S

doi: 10.1016/j.semarthrit.

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis

Arthritis Rheumatol.

Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, Toniolo M, Exer P, Gabay C, Finckh A; physicians of the Swiss Clinical Quality Management Cohort

doi: 10.1002/art.39691.

Psoriatic Arthritis

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients

Arthritis Res Ther.

Simon D, Kleyer A, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Petrov R, Liphardt AM, Rech J, Schett G, Hueber AJ

doi: 10.1186/s13075-019-1938-3.

Rheumatoid Arthritis

Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review

J Rheumatol.

Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS

doi: 10.3899/jrheum.181165.

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS

doi: 10.1016/

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

doi: 10.1016/S0140-

Rheumatoid Arthritis

Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial

JAMA.

Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P

doi: 10.1001/jama.2016.13512.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

J Autoimmun.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R

doi: 10.1016/j.jaut.2020.102468.

Spinal Disorders

Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis

Rheumatology (Oxford).

Cruz-Machado AR, Rodrigues-Manica S, Silva JL, Alho I, Coelho C, Duarte J, Florêncio C, Pimentel-Santos FM, Tavares-Costa J, Vieira-Sousa E

doi: 10.1093/rheumatology/keaa268.

Related content

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients

Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis